257 related articles for article (PubMed ID: 33889834)
1. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
2. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
5. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
You MW; Kim KW; Shim JJ; Pyo J
J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
[TBL] [Abstract][Full Text] [Related]
6. Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Luo JC; Lee IC; Chi CT; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2024 Apr; 87(4):357-368. PubMed ID: 38180018
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness.
Dajti E; Marasco G; Ravaioli F; Colecchia L; Ferrarese A; Festi D; Colecchia A
JHEP Rep; 2021 Jun; 3(3):100289. PubMed ID: 34095798
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model.
Dhiman RK; Grover GS; Premkumar M; Roy A; Taneja S; Duseja A; Arora S;
EClinicalMedicine; 2021 Nov; 41():101148. PubMed ID: 34712928
[TBL] [Abstract][Full Text] [Related]
9. Diabetic patients with chronic hepatitis C virus response compared to non diabetics when treated with directly acting antiviral therapy.
Marzaban RN; AlMekhzangy HI; ElAkel W; ElBaz TM; ElShazly YM; ElSaeed K; Anees M; Said M; ElSerafy MA; Esmat GG; Doss WH
Arab J Gastroenterol; 2024 Feb; ():. PubMed ID: 38378359
[TBL] [Abstract][Full Text] [Related]
10. Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center.
Karbeyaz F; Kissling S; Jaklin PJ; Bachofner J; Brunner B; Müllhaupt B; Winder T; Mertens JC; Misselwitz B; von Felten S; Siebenhüner AR
J Hepatocell Carcinoma; 2021; 8():565-574. PubMed ID: 34150679
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
12. Biochemical predictors of hepatocellular cancer development after one year in patients who achieved HCV clearance by direct-acting antiviral treatment.
Sargin ZG; Dusunceli I
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(22):8459-8466. PubMed ID: 36459043
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma: A meta-analysis.
Li CF; Tsao SM; Liao HH; Chen SC; Lee YT
Medicine (Baltimore); 2020 Oct; 99(40):e22435. PubMed ID: 33019424
[TBL] [Abstract][Full Text] [Related]
15. Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia.
Kim IJ; Yoo SH; Kim S; Cho YY; Yoo KY; Kim HJ; Lee HW
J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268541
[TBL] [Abstract][Full Text] [Related]
16. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
Ioannou GN; Green PK; Berry K
J Hepatol; 2017 Sep; ():. PubMed ID: 28887168
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment nonalcoholic fatty liver disease fibrosis scores for predicting liver-related complications in patients with chronic hepatitis C receiving direct-acting antiviral agents.
Hsu WF; Lai HC; Chuang PH; Su WP; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
J Viral Hepat; 2022 Sep; 29(9):785-794. PubMed ID: 35657121
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
[TBL] [Abstract][Full Text] [Related]
19. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
20. Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy.
Hu CC; Weng CH; Chang LC; Lin CL; Chen YT; Hu CF; Hua MC; Chen LW; Chien RN
Ther Clin Risk Manag; 2018; 14():783-791. PubMed ID: 29750037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
